CNCR vs. ARKG
CNCR (Loncar Cancer Immunotherapy ETF) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. CNCR is passively managed, while ARKG is actively managed. CNCR charges 0.79%/yr vs 0.75%/yr for ARKG.
Performance
CNCR vs. ARKG - Performance Comparison
Loading charts...
Returns By Period
CNCR
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ARKG
- 1D
- -2.16%
- 1M
- 12.21%
- YTD
- 17.36%
- 6M
- 14.32%
- 1Y
- 57.12%
- 3Y*
- 0.75%
- 5Y*
- -15.45%
- 10Y*
- 7.24%
CNCR vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | |
|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 18.10% |
CNCR vs. ARKG - Sectors Allocation Comparison
Sectors
CNCR
ARKG
Healthcare
Financial Services
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
CNCR
ARKG
Financial Services
CNCR
ARKG
Basic Materials
CNCR
-
ARKG
-
Communication Services
CNCR
-
ARKG
-
Consumer Cyclical
CNCR
-
ARKG
-
Consumer Defensive
CNCR
-
ARKG
-
Energy
CNCR
-
ARKG
-
Industrials
CNCR
-
ARKG
-
Real Estate
CNCR
-
ARKG
-
Technology
CNCR
-
ARKG
-
Utilities
CNCR
-
ARKG
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CNCR vs. ARKG — Risk / Return Rank
CNCR
ARKG
CNCR vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Sharpe Ratios by Period
| CNCR | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 1.40 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.34 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | — | 0.13 | — |
Drawdowns
CNCR vs. ARKG - Drawdown Comparison
The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for CNCR and ARKG.
Loading charts...
Drawdown Indicators
| CNCR | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | 0.00% | -83.59% | +83.59% |
Max Drawdown (1Y)Largest decline over 1 year | — | -27.51% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -51.96% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -80.18% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.59% | — |
Current DrawdownCurrent decline from peak | 0.00% | -69.58% | +69.58% |
Average DrawdownAverage peak-to-trough decline | 0.00% | -35.86% | +35.86% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 11.46% | — |
Volatility
CNCR vs. ARKG - Volatility Comparison
Loading charts...
Volatility by Period
| CNCR | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 11.89% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 29.12% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 0.00% | 41.24% | -41.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 0.00% | 45.62% | -45.62% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 0.00% | 41.13% | -41.13% |
CNCR vs. ARKG - Expense Ratio Comparison
CNCR has a 0.79% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Dividends
CNCR vs. ARKG - Dividend Comparison
Neither CNCR nor ARKG has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
On fees, ARKG is cheaper at 0.75% per year. The better choice depends on whether you care most about return, fees, risk, or income.
ARKG is cheaper with a 0.75% expense ratio, compared with 0.79% for CNCR.
CNCR and ARKG have nearly identical dividend yields, around 0.00%.
They also come from different issuers: Exchange Traded Concepts and ARK. Their fees differ too: 0.79% for CNCR and 0.75% for ARKG.
Find the right allocation for CNCR and ARKG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer